CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
COVID-19 Convalescent Plasmabiological
Likely dose
COVID-19 Convalescent Plasma 2 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04388527
NCT04388527Phase 1Completed
CompareCT.gov

An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2

University of Pennsylvania·interventional·Posted May 14, 2020·Updated Apr 4, 2022

In Brief

A Phase 1 clinical trial evaluating COVID-19 Convalescent Plasma for Covid-19. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it can improve patients' health when they are sick with COVID-19.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid-19
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedMay 14, 2020
Enrollment StartApr 30, 2020
Primary CompletionJan 25, 2021
Study CompletionJan 30, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.1 years ago

Interventions

COVID-19 Convalescent Plasmabiological

Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.